This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

Early Bird pricing expires in:

  • 00
  • 00
  • 00
  • 00
Delivered In-Person & Digitally
March 28–30, 2022, Basel, SwitzerlandApril 4–6, 2022, Digital Partnering

Jay Foust
Executive Director Business Development, Translational Medicine at Bristol Myers Squibb


Jay Foust is the Executive Director of Business Development, Translational Medicine at Bristol-Myers Squibb. Jay brings a breadth of technology and product perspective, having worked closely with the most widely adopted and stable solutions in clinical practice to the most innovative and promising yet least widely adopted solutions. Having negotiated collaboration agreements from both the pharma perspective and the diagnostics perspective, he brings a wide perspective of transactional issues, nuances and tendencies between companies and technologies, and best practices across the industry.

Prior to BMS, Jay was busy helping fight the pandemic. He supported the NIH’ Rapid Acceleration of Diagnostics (RADx) program ( designed to facilitate the development and scale up of SARS-CoV-2 testing. Prior to RADx, Jay was SVP, Business Development at Personal Genome Diagnostics (, as a member of the leadership team the role spanned all areas of Business Development. Before PGDx, he spent 10 years at Ventana Medical Systems, a member of the Roche Group, in increasing strategic marketing and business development roles. Prior to Roche, he spent 10 years with increasing responsibility in early stage venture capital with Research Corporation Technologies (

Jay is an avid baseball and Arizona Wildcat fan, initially attending the university as a third string backup bullpen catcher, and leaving a few years later with a bachelor’s degree in Molecular and Cellular Biology and a MBA with a concentration on entrepreneurship. He further studied intellectual property law and patent prosecution to round out his education to include science, business, and IP law.

Agenda Sessions

  • Health disruptors: Innovative technologies

    On Demand